Walter Franziska, Federman Noah, Apichairuk Wipapat, Nelson Scott, Phelps Michael E, Allen-Auerbach Martin, Walter Martin A, Czernin Johannes
Ahmanson Translational Imaging Division and Department of Molecular and Medical Pharmacology, University of California-Los Angeles, CA, USA
Pediatr Hematol Oncol. 2011 Oct;28(7):579-87. doi: 10.3109/08880018.2011.602180.
A high (18)F-fluorodeoxyglucose (FDG) uptake by positron emission tomography/computed tomography (PET/CT) imaging in sarcomas of adults has been reported. The current study aimed at defining the degree of (18)F-FDG uptake of pediatric sarcomas. This retrospective study included 29 patients (23 males, 6 females; mean age 14 ± 5 years) with soft tissue (n = 9) or bone (n = 20) sarcomas. Twenty-two patients (76%) underwent (18)F-FDG PET/CT and 7 (24%) had dedicated (18)F-FDG PET studies. Tumor (18)F-FDG uptake was quantified by standard uptake value (SUV)(max) and tumor-to-liver ratios (SUV ratios; tumor SUV(max)/liver SUV(mean)). Tumor SUV(max) and SUV ratios were correlated with tumor Ki-67 expression. SUV(max) ranged from 1.4 to 24 g/mL (median 2.5 g/mL) in soft tissue sarcomas and 1.6 to 20.4 g/mL (median 6.9 g/mL) in bone sarcomas (P = .03), and from 1.6 to 9.2 g/mL (median 3.9 g/mL) and 3.5 to 20.4 g/mL (median 12 g/mL) in Ewing sarcoma and osteosarcoma, respectively (P = .009). Tumor SUV ratios ranged from 0.8 to 8.7 (median 1.9) in soft tissue sarcomas and 1.4 to 8.9 (median 3.8) in bone sarcomas (P = .08). Ewing sarcoma had a significantly lower tumor SUV ratio than osteosarcoma (P = .01). Ki-67 expression correlated significantly with the (18)F-FDG uptake in bone but not in soft tissue sarcomas. All sarcomas were visualized by (18)F-FDG PET/CT imaging. A higher (18)F-FDG uptake was observed in osteosarcoma than in Ewing and soft tissue sarcomas. The results of this study suggest that the degree of tumor (18)F-FDG uptake is sufficient to allow for monitoring of therapeutic responses in pediatric sarcomas.
据报道，正电子发射断层扫描/计算机断层扫描（PET/CT）成像显示成人肉瘤中（18）F-氟脱氧葡萄糖（FDG）摄取量较高。本研究旨在确定儿童肉瘤的（18）F-FDG摄取程度。这项回顾性研究纳入了29例软组织肉瘤（n = 9）或骨肉瘤（n = 20）患者（23例男性，6例女性；平均年龄14±5岁）。22例患者（76%）接受了（18）F-FDG PET/CT检查，7例（24%）进行了专门的（18）F-FDG PET研究。通过标准摄取值（SUV）（max）和肿瘤与肝脏比值（SUV比值；肿瘤SUV（max）/肝脏SUV（mean））对肿瘤（18）F-FDG摄取进行定量。肿瘤SUV（max）和SUV比值与肿瘤Ki-67表达相关。软组织肉瘤的SUV（max）范围为1.4至24 g/mL（中位数2.5 g/mL），骨肉瘤为1.6至20.4 g/mL（中位数6.9 g/mL）（P = 0.03），尤因肉瘤和骨肉瘤分别为1.6至9.2 g/mL（中位数3.9 g/mL）和3.5至20.4 g/mL（中位数12 g/mL）（P = 0.009）。软组织肉瘤的肿瘤SUV比值范围为0.8至8.7（中位数1.9），骨肉瘤为1.4至8.9（中位数3.8）（P = 0.08）。尤因肉瘤的肿瘤SUV比值显著低于骨肉瘤（P = 0.01）。Ki-67表达与骨肉瘤中的（18）F-FDG摄取显著相关，但与软组织肉瘤无关。所有肉瘤均可通过（18）F-FDG PET/CT成像显示。观察到骨肉瘤中的（18）F-FDG摄取高于尤因肉瘤和软组织肉瘤。本研究结果表明，肿瘤（18）F-FDG摄取程度足以用于监测儿童肉瘤的治疗反应。
